Protalix BioTherapeutics (PLX) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.27 --0%
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
AQMS, HWBK, RJET, More
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
AQMS, HWBK, RJET, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $62.89 million versus the consensus estimate of $6.12 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ingram Micro Holding Corporation (INGM) Tops Q2 EPS by 4c
- Minerals Technologies (MTX) Misses Q2 EPS by 3c
- NCS Multistage Holdings, Inc. (NCSM) Misses Q2 EPS by 134c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
